The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes

Daily Roundup | Hovilpri Wins FDA Approval & Biohaven Licenses BHV-1300 to Ono for $80M at Closing

Friday, October 9 edition, released late Saturday, October 10. FDA approved Hovilpri (pritelivir) for immunocompromised adults with stubborn herpes simplex lesions, but

Daily Roundup | Tecentriq Approved After dMMR Colon Cancer Surgery & Zenbexus Topline: Median PFS 42 vs 20 Months

Thursday, October 8 edition, published after midnight Pacific. FDA approves Roche's Tecentriq (atezolizumab) with chemotherapy after stage III dMMR colon cancer surgery:

Daily Roundup | Pfizer Adds a Breast Cancer Maintenance Choice & MimiVax's Brain Cancer Vaccine Misses

Pfizer's Tukysa (tucatinib) wins a breast cancer maintenance approval after delaying progression, while MimiVax's SurVaxM misses its overall glioblastoma survival goal de

Daily Roundup | ArriVent’s Lung Cancer Pill Hits Setback & Alector’s $100M Genentech Deal

ArriVent's firmonertinib missed its Phase 3 primary progression-free-survival endpoint in lung cancer, with its next step still undecided; this delayed Tuesday edition wa

EASD 2026 Debrief: Type 2 Diabetes Care Moves Earlier & Foundayo Meets a Heart-Safety Bar

The Pharma Closeout's EASD 2026 Debrief covers the readouts from the European Association for the Study of Diabetes meeting in Milan that matter for drug, device and paye

Daily Roundup | Genmab's Epkinly Wins Frontline Trial & Vaxcyte's Vaccine Passes With Caveats

Genmab and AbbVie's investigational frontline Epkinly (epcoritamab) combination cut progression-or-death hazard 51% versus R-CHOP in lymphoma patients with IPI scores of

Week in Review | Lilly's Retatrutide Dose Data, Novartis' RNA Deal & Jaypirca's Approval

Lilly's retatrutide detail reveals that adverse-event discontinuations peaked below the top dose, while Jaypirca gains first-line CLL and SLL approval for adults without

ASTRO 2026 Debrief: Who Still Needs Hormone Therapy & Protons vs Photons in Liver Cancer

The Pharma Closeout's ASTRO 2026 Debrief covers the readouts from the American Society for Radiation Oncology meeting that matter for drug,diagnostic and payer strategy.

Daily Roundup | Jaypirca Adds a First-Line CLL Choice & Novartis Signs $575M Abogen License

Delayed Friday edition, recorded October 2. Lilly's Jaypirca (pirtobrutinib) gains first-line approval for adults with CLL/SLL without a known 17p deletion—but how does a

Daily Roundup | Survodutide Phase 3 Comes With GI Tolerability Cost & Trevogrumab Trims Lean-Tissue Loss on Scans

Boehringer's survodutide reached up to 13.1% weight loss in Phase 3 assuming patients stayed on treatment, but GI-related dropouts complicate its place in obesity and Typ

Daily Roundup | Lilly's amylin add-on brings more weight loss and more dropouts & Rafael plans NDA after NPC miss

September 30 edition, released October 1. Date references in the audio are anchored to September 30. Lilly's EloraTZP (eloralintide plus tirzepatide) reached 23.3% weigh

Daily Roundup | uniQure's Mixed Huntington's Readout & AstraZeneca's $2B Summit Deal

September 29 edition: uniQure's four-year Huntington's readout is mixed, while its filing rests on earlier data. AstraZeneca agrees to invest $2 billion in Summit alongsi

Daily Roundup| Mirum's Brelovitug Wins Phase 3 on Two Schedules & Kodiak's Zenkuda: 54% Reach Six-Month Dosing

Mirum's brelovitug met Phase 3 AZURE-1's virus-plus-ALT endpoint on weekly and every-four-week dosing in chronic hepatitis delta; durable liver outcomes were not shown. K

Full Week in Review | Gilead's Anito-cel, Genentech's Gazyva & Myeloma's New Cure Standard

This full Week in Review is a comprehensive review of the week's covered stories across oncology, kidney and immune disease, respiratory disease, metabolic disease, neuro

Daily Roundup | Mirum Wins FOP Approval Despite Primary Endpoint Miss & Carvykti's Five-Year Data

Mirum's Atebrioz (zilurgisertib) wins FDA approval for FOP despite a primary-endpoint miss; Carvykti (ciltacabtagene autoleucel) shows five-year disease control without m

Daily Roundup| Merck–Eisai Win Kidney Cancer Approval & Lilly Joins Weekly Insulin Race

Welireg plus Lenvima gains FDA approval in advanced clear-cell kidney cancer, with better disease control but no demonstrated survival advantage. Lilly says FDA approved

Daily Roundup| GRAIL's Galleri Vote Puts Label and Coverage in Focus & Roche Posts Phase 3 Kidney Win

GRAIL’s Galleri won backing from FDA advisers, but the narrow effectiveness split and a missed late-stage-cancer endpoint keep the label and coverage case in focus. Roche

Celldex Safety Clouds Pivotal Wins & Otsuka–Ionis ALS Trial Hits Joint Endpoint

Celldex's pivotal barzolvolimab wins in chronic hives carry an anaphylaxis signal. Otsuka and Ionis report a joint-endpoint ALS result for ulefnersen, while Iambic's IPO

Beacon Gene Therapy Meets Pivotal Vision Endpoint & Telix Strikes $1.65B ITM Deal

Beacon’s pivotal VISTA trial met its endpoint in inherited vision loss, with low-light gains and surgical risks shaping the next questions. Telix’s $1.65 billion ITM deal

Week in Review | Novo’s Obesity Choices & Ivonescimab’s Global Test

Novo adds obesity programs as its Ascendis collaboration ends, while ivonescimab's China survival results sharpen the test facing its global lung-cancer program. Europe m